Reducing the risk of at-home chemo complications with remote monitoring

Each year, more than one million people in the US receive chemotherapy, a standard treatment for many types of cancer. More than half of those patients now receive treatment through outpatient departments, and most patients who receive chemo are sent home the same day. This practice places the burden of reporting emergent side effects on patients, which can put them at risk for serious complications such as neutropenic fever and cardiac arrhythmias.

Patients recovering at home are likely to miss the early signs of common side effects, even when warned about them. While they are typically sent home with instructions for self-monitoring potential symptoms and are told to contact their care team if they detect onset of an adverse event, symptoms can be difficult to distinguish from the effects of chemo treatment and can have multiple underlying causes. The self-reporting method also depends on patients adhering to instructions to take their own temperature and accurately monitor health symptoms while contending with the fatigue and general malaise that often accompany treatment.

I have spent the past eleven years building wearable sensors to close this gap, and the lesson has been consistent: the complications that hurt patients most are the ones nobody was watching for at the time. Remote patient monitoring (RPM) of vitals takes away the uncertainty of leaving symptom detection to patients. For them, RPM makes it easier to focus on rest and recovery at-home, which has been shown to increase patient well-being and promote positive recovery outcomes. There is also a cost benefit for care providers, because patients whose symptoms are safely managed at home are far less likely to wind up in the hospital, saving resources and keeping beds open for acute patients.

Common, preventable side effects of chemo

Two common side effects of chemo, neutropenic fever and cardiac arrhythmia, provide an example of why RPM matters for oncology patients. Neutropenic fever typically occurs seven to 14 days after infusion, when the patient’s white blood cell count drops critically low from treatment and leaves the body unable to mount its normal defenses against infection. At that point, fever is often the only warning system still functioning if an infection occurs. While the source of an infection could be anything, chemo patients have an increased risk of infection from their own body’s bacteria, because chemo damages the mucosal lining that normally keeps gut bacteria contained. If left untreated, such infections can progress rapidly to sepsis and become life-threatening.

Several classes of chemo drugs also carry an innate risk of cardiotoxicity, potentially causing heartbeat irregularities and heart muscle damage that increase a patient’s risk of cardiac arrest. While patients are given a list of symptoms to watch out for, studies have shown that as many as half of patients with arrhythmias are asymptomatic, making self-reporting unreliable.

How remote monitoring reduces side effect risk

Research has shown that RPM wearables are effective for catching complications from chemo before they escalate. A study of neutropenic fever and wearable temperature monitors found that RPM devices could catch signs of fever 82% of the time and about an hour earlier than standard thermometer checks. This is distinct from traditional monitoring protocols. A thermometer check twice a day cannot catch a fever that starts at 2 a.m., and a symptom checklist cannot catch an arrhythmia the patient never feels. Continuous wearable monitoring that captures temperature and ECG together, from a single sensor, provides two solutions at once: it removes the reliance on the patient to notice, measure, and report, and it gives the care team a live signal instead of a delayed one.

RPM also helps to catch arrhythmias and other heart complications from chemo. In a trial with 122 chemo patients, RPM successfully detected 82 cardiotoxic events prior to the standard follow-up appointment. In one study of cardiac patients, ECG wearables caught instances of postoperative atrial fibrillation (AFib), a type of arrhythmia, that went undetected during hospitalisation. In 80% of those cases, AFib wasn’t diagnosed using standard modalities until the standard three-month follow up. The findings remain relevant for oncology patients because arrhythmias may show up weeks or even months after treatment, making ongoing RPM critical for getting patients timely care.

Even programmes that still depend on patients to report their own symptoms show the value of earlier intervention: a randomised trial of nurse-led telehealth symptom monitoring for chemotherapy patients found a 57% reduction in overall symptom burden, along with fewer days spent with moderate or severe symptoms across multiple side effect categories. Continuous vitals monitoring takes that a step further by removing the reliance on the patient to notice and report at all. It also allows care teams to prioritise their response. Rather than treating every patient contact as equally urgent, monitoring platforms can flag high-risk vitals for immediate clinical attention while routing lower-acuity concerns through standard channels, allowing nurses and oncologists to direct their attention where it matters most.

The business case for better patient outcomes

RPM technology is reshaping early detection, which provides both patients and care providers numerous downstream benefits. It leads to fewer emergency room visits, shorter hospital stays, and more time for patients to recover in the comfort of home, rather than in an acute care bed. Recent research on patients with blood cancers found that RPM programmes meaningfully reduced infection-related emergency visits and hospital admissions, generating close to $1 million in savings for every 1,000 patients monitored annually.

Broader oncology data shows a similar pattern. One study examining patients with metastatic solid tumours found a 28% reduction in hospitalisations among those using a remote monitoring platform, translating to an estimated $3.19 million in hospitalisation savings and $93,330 in emergency department visit savings per 1,000 patients annually.

Reducing emergency visits and hospitalisations is also important following greater scrutiny from Medicare, which has attached a penalty of up to 2% on reimbursement for hospitals with higher-than-expected rates of emergency visits or hospitalisations linked to 10 specific conditions within 30 days of chemo, including fever and neutropenia.

Advancing patient care, reducing inpatient burden

The case for RPM in oncology rests on a rare alignment of incentives: patients benefit from earlier detection of dangerous complications, reduced symptom burden, and more time recovering at home, rather than in a hospital bed, while health systems benefit from fewer preventable hospitalisations and reduced draw on resources. RPM delivers on both fronts at once, giving patients a smoother recovery while giving health systems a stronger financial position. As reimbursement models increasingly tie payment to a system's ability to keep patients out of the hospital, that alignment will only become more consequential, and broader implementation across outpatient oncology, where the majority of chemotherapy and the majority of risk currently live, is likely to follow.

About the author

Jiang Li, PhD, is the founder and CEO of Vivalink, Inc., developing digital health technology solutions for remote patient monitoring in healthcare and clinical research. Prior to Vivalink, Li held positions as VP of engineering at Thin Film Electronics, Kovio, and Spansion, as well as director of product engineering at Advanced Micro Devices.